# reload+after+2024-01-23 11:46:19.173856
address1§21 Firstfield Road
city§Gaithersburg
state§MD
zip§20878
country§United States
phone§240 268 2000
website§https://www.novavax.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
fullTimeEmployees§1992
companyOfficers§[{'maxAge': 1, 'name': 'Mr. John Joseph Trizzino B.S., M.B.A.', 'age': 63, 'title': 'President & COO', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 641216, 'exercisedValue': 0, 'unexercisedValue': 213608}, {'maxAge': 1, 'name': 'Mr. James Patrick Kelly C.F.A.', 'age': 57, 'title': 'Executive VP, CFO & Treasurer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 644322, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stanley Charles Erck', 'age': 75, 'title': 'Advisor', 'yearBorn': 1948, 'fiscalYear': 2022, 'totalPay': 1090317, 'exercisedValue': 0, 'unexercisedValue': 487116}, {'maxAge': 1, 'name': 'Mr. John Charles Jacobs M.B.A.', 'age': 56, 'title': 'CEO & Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Richard P. Crowley', 'age': 66, 'title': 'Executive VP & COO', 'yearBorn': 1957, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  Casey', 'title': 'Executive VP, Chief Legal Officer & Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Erika S. Trahan', 'title': 'Associate Director of Investor & Public Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ian J. Watkins', 'age': 60, 'title': 'Executive VP & Chief Human Resources Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Silvia  Taylor M.B.A.', 'title': 'Executive VP and Chief Corporate Affairs & Advocacy Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Filip  Dubovsky FAAP, M.D., M.P.H.', 'age': 58, 'title': 'President of Research & Development', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§4
compensationRisk§5
shareHolderRightsRisk§5
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.524
priceToSalesTrailing12Months§0.56579494
currency§USD
dateShortInterest§1702598400
forwardEps§-0.72
pegRatio§0.02
exchange§NMS
quoteType§EQUITY
shortName§Novavax, Inc.
longName§Novavax, Inc.
firstTradeDateEpochUtc§818173800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§cdb3cddb-5091-3918-86d6-9b4894e61c6c
gmtOffSetMilliseconds§-18000000
targetHighPrice§38.0
targetLowPrice§5.0
targetMeanPrice§19.6
targetMedianPrice§12.0
recommendationMean§2.7
recommendationKey§hold
numberOfAnalystOpinions§5
quickRatio§0.528
grossMargins§-0.1416
ebitdaMargins§-0.54762
trailingPegRatio§None
